最新观点
Insights From Our Experts
Articles
Realign Access Strategies to Overcome Challenges of Co-pay Assistance and Cost Sharing Trends
Kevin O’Meara, EVERSANA’s Vice President of Patient Services Solutions, joined Peter Avalos, National Reimbursement Director at Daiichi Sankyo, Inc., to discuss the current challenges impeding patient access and how to best optimize your co-pay programs using customized solutions and digital innovations.
American Medical Association Discusses New CPT Codes to Identify Digital Health Services
In our last update, we discussed the proposed rule that the Centers for Medicare and Medicaid Services (CMS) issued regarding the addition of certain Current Procedural Terminology (CPT®) codes to identify remote therapeutic monitoring (RTM) in…
CMS Releases Remote Therapeutic Monitoring Codes for 2022
The Centers for Medicare and Medicaid Services (CMS) released the proposed Medicare physician fee schedule regulation for 2022, which includes an analysis and payment calculations for the new Remote Therapeutic Monitoring (RTM) CPT codes issued by…
BLOG: ‘Bundling’ Payments to Assure Appropriate Rx Use
Posted by
Dr. Richard Stefanacci on 8 月 6, 20218/6/21
In Medicare’s drive to improve outcomes of the fee-for-service (FFS) payment model, this model is being replaced with value-based care. The delivery of value-based care is not supported by FFS payments, which incentivize the volume of…
Competitive Benchmarking In Trade – Answering The Who, What, Why and When
Last month our colleague Derek Cothran addressed the importance of using secondary research to benchmark your Patient Support Program (PSP) against obvious and not-so-obvious competitors. We’d like to continue a discussion around competitive benchmarking in this…
Breaking through Barriers: Critical Success Factors for Launching Products with Breakthrough Therapy Designation
Posted by
Siddharth Agrawal , Andrew Therrien, PhD , Mark D. Bogost , Vivienne Ho, PhD on 7 月 26, 20217/26/21
The FDA’s Breakthrough Therapy Designation (BTD) expedites patient access to innovative new treatments. While speeding up these processes can get new drugs to patients in need faster than they normally would through standard tracks, limited clinical…
BLOG: Pharmaceutical Value-based Contracts: Adherence and Supportive Contracts
Posted by
Dr. Richard Stefanacci on 7 月 20, 20217/20/21
While there is a great deal of talk regarding value-based contracts in the life sciences industry, there are few successful examples. The difficulties in structuring these contracts begin with identification of outcomes that are directly and…
Navigating the Transition to Post-Approval Pharmacovigilance With EVERSANA and ArisGlobal
Partnering with a contract research organization (CRO) provider during clinical development fills an important role in the product life cycle, providing pharmaceutical companies with pharmacovigilance expertise and support during clinical trials. After product approvals, it can…
Case Study: Launching a New Therapy for HER2-Positive Metastatic Breast Cancer
When MacroGenics partnered with EVERSANA, they had less than five months to launch their first product in the midst of the global pandemic. To meet their timeline and streamlined launch, MacroGenics needed a commercialization partner with…
The Patient Access Paradox: How the New CMS Rule Could Prioritize Drug Pricing Before Clinical Decision-Making
In January 2023, co-pay programs will be put to the test, consequently examining how well your brand can adapt to the Final Rule changes to meet patient and provider needs. Our recommendation: Don’t wait – start…